netFormulary South East London Joint Medicines Formulary NHS
Guy's and St Thomas' NHS Foundation Trust
Kings College Hospital NHS Foundation Trust
Lewisham and Greenwich NHS Trust
 
 Search
 Formulary Chapter 11: Eye - Full Chapter
Notes:

Where a formulary entry does not detail a medicine’s indications for use, the medicine can be assumed to be approved for all licensed indications.

Formulary approved "off-label" use is detailed separately.

 Details...
11.08.02  Expand sub section  Ocular diagnostic and peri-operative preparations and photodynamic treatment
11.08.02  Expand sub section  Ocular diagnostic preparations
11.08.02  Expand sub section  Ocular peri-operative drugs
11.08.02  Expand sub section  Subfoveal choroidal neovascularisation
Aflibercept intravitreal injection
View adult BNF View SPC online
Formulary
Red
High Cost Medicine

Approved as per NICE technology appraisal guidance

Refer to APC guidance for Wet Age-Related Macular Degeneration, Diabetic Macular Oedema, Central Retinal Vein Occlusion and Branch Retinal Vein Occlusion (see link below)

 
Link  NICE TA294: Macular degeneration (wet age-related) - aflibercept
Link  NICE TA305: Aflibercept for treating visual impairment caused by macular oedema secondary to central retinal vein occlusion
Link  NICE TA346: Aflibercept for treating diabetic macular oedema
Link  NICE TA409: Aflibercept for treating visual impairment caused by macular oedema after branch retinal vein occlusion
Link  NICE TA486: Aflibercept for treating choroidal neovascularisation
   
Dexamethasone intravitreal implant (Ozurdex )
View adult BNF View SPC online
Formulary
Red
High Cost Medicine

Approved as per NICE technology appraisal guidance

Refer to APC guidance for Wet Age-Related Macular Degeneration, Diabetic Macular Oedema, Central Retinal Vein Occlusion and Branch Retinal Vein Occlusion (see link below)

 
Link  NICE TA229: Dexamethasone intravitreal implant for the treatment of macular oedema
Link  NICE TA349: Dexamethasone intravitreal implant for treating diabetic macular oedema
Link  NICE TA460: Adalimumab and dexamethasone for treating non-infectious uveitis
   
Fluocinolone intravitreal implant (Iluvien)
View adult BNF View SPC online
Formulary
Red
High Cost Medicine

Approved as per NICE technology appraisal guidance

Refer to APC guidance for Wet Age-Related Macular Degeneration, Diabetic Macular Oedema, Central Retinal Vein Occlusion and Branch Retinal Vein Occlusion (see link below)

 
Link  NICE TA301: Fluocinolone acetonide intravitreal implant for treating chronic diabetic macular oedema after an inadequate response to prior therapy (rapid review of technology appraisal guidance 271)
   
Ranibizumab intravitreal injection
View adult BNF View SPC online
Formulary
Red
High Cost Medicine

Approved as per NICE technology appraisal guidance

Refer to APC guidance for Wet Age-Related Macular Degeneration, Diabetic Macular Oedema, Central Retinal Vein Occlusion and Branch Retinal Vein Occlusion (see link below)

 
Link  NICE TA155: Ranibizumab and pegaptanib for the treatment of age-related macular degeneration
Link  NICE TA274: Macular oedema (diabetic) - ranibizumab
Link  NICE TA283: Macular oedema (retinal vein occlusion) - ranibizumab: guidance
Link  NICE TA298: Choroidal neovascularisation (pathological myopia) - ranibizumab
   
Verteporfin injection (chronic central serous chorio-retinopathy - off-label)
View adult BNF View SPC online
Formulary
Red
High Cost Medicine

Approved off-label use:

Treatment of chronic central serous chorio-retinopathy (CSC)

Restricted to Consultant Specialists in medical retinal disease

 
   
Verteporfin injection (licensed use)
View adult BNF View SPC online
Formulary
Red
High Cost Medicine

Refer to NICE NG82 for details on approved use of photodynamic therapy

 
Link  NICE NG82: Age-related macular degeneration
   
Bevacizumab intravitreal injection (1.25 mg in 0.05 mL)
View adult BNF View SPC online
Unlicensed Drug Unlicensed
Red
Approved for:
  • Neovascular glaucoma
  • Rubeosis iridis (iris neovascularisation) not responding to conventional treatment
  • Use prior to vitrectomy surgery in severe proliferative diabetic retinopathy  
  •    
    11.08.02  Expand sub section  Vitreomacular traction to top
     ....
     Non Formulary Items
    Pegaptanib intravitreal injection

    View adult BNF View SPC online
    Non Formulary
    Grey

    Not approved for use in SE London

    See NICE TA155

     
      
    Key
    note Notes
    Section Title Section Title (top level)
    Section Title Section Title (sub level)
    First Choice Item First Choice item
    Non Formulary Item Non Formulary section
    Restricted Drug
    Restricted Drug
    Unlicensed Drug
    Unlicensed
    Track Changes
    Display tracking information
    click to search medicines.org.uk
    Link to adult BNF
    click to search medicines.org.uk
    Link to SPCs
    SMC
    Scottish Medicines Consortium
    Cytotoxic Drug
    Cytotoxic Drug
    CD
    Controlled Drug
    High Cost Medicine
    High Cost Medicine
    Cancer Drugs Fund
    Cancer Drugs Fund
    NHSE
    NHS England
    Homecare
    Homecare
    CCG
    CCG

    Traffic Light Status Information

    Status Description

    Red

    Specialist or hospital prescribing only. The responsibility for prescribing, monitoring, dose adjustment and review should remain with the specialist or hospital. In very exceptional circumstances a specialist may discuss individual patient need for a RED drug to be prescribed by a GP and the GP should consider informing the Medicines Management team before a decision is made to prescribe for individual patients.   

    Amber 1

    Treatment can be initiated in primary care after a recommendation from an appropriate specialist  

    Amber 2

    Specialist initiation followed by maintenance prescribing in primary care  

    Amber 3

    Specialist initiation with ongoing monitoring required. After dose stabilisation GPs can be requested to take over prescribing responsibilities using the approved APC shared care documentation  

    Green

    Specialist and non-specialist initiation  

    Grey

    Not recommended for prescribing  

    netFormulary